Financial Summary (All financials)
| In millions of CNY, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 7,237.0 | 8,658.6 | 8,420.8 | 7,233.2 | 6,210.2 | 5,961.6 | 3,464.0 | 2,132.9 |
| Revenue growth | -16.4% | 2.8% | 16.4% | 16.5% | 4.2% | 72.1% | 62.4% | 75.3% |
| Cost of goods sold | 1,047.9 | 961.2 | 960.3 | 820.3 | 1,358.7 | 2,393.2 | 669.1 | 381.5 |
| Gross profit | 6,189.1 | 7,697.4 | 7,460.5 | 6,412.9 | 4,851.5 | 3,568.5 | 2,794.9 | 1,751.5 |
| Gross margin | 85.5% | 88.9% | 88.6% | 88.7% | 78.1% | 59.9% | 80.7% | 82.1% |
| Sales and marketing | 2,759.9 | 3,246.5 | 3,093.3 | 2,435.2 | 1,647.5 | 1,536.9 | 1,127.5 | 559.1 |
| Research and development | 1,398.0 | 1,364.2 | 1,291.1 | 1,135.2 | 878.8 | 571.4 | 273.9 | 158.4 |
| General and administrative | 543.8 | 381.8 | 318.0 | 314.8 | 282.0 | 306.8 | 193.7 | 129.8 |
| EBITA | 1,865.6 | 3,158.8 | 3,248.1 | 2,905.3 | 2,048.2 | 1,165.2 | 1,205.2 | 910.3 |
| EBITA margin | 25.8% | 36.5% | 38.6% | 40.2% | 33.0% | 19.5% | 34.8% | 42.7% |
| Amortization of intangibles | 83.7 | 12.0 | 11.7 | 11.6 | 6.9 | 4.6 | 5.2 | 6.1 |
| EBIT | 1,781.9 | 3,146.8 | 3,236.5 | 2,893.6 | 2,041.3 | 1,160.7 | 1,199.9 | 904.2 |
| EBIT margin | 24.6% | 36.3% | 38.4% | 40.0% | 32.9% | 19.5% | 34.6% | 42.4% |
| Pre-tax income | 2,177.2 | 3,668.5 | 3,701.0 | 3,241.4 | 2,261.5 | 1,248.9 | 1,276.2 | 941.5 |
| Income taxes | 34.0 | 260.9 | 500.4 | 377.9 | 267.1 | 32.6 | 285.5 | 192.8 |
| Tax rate | 1.6% | 7.1% | 13.5% | 11.7% | 11.8% | 2.6% | 22.4% | 20.5% |
| Net income | 2,148.6 | 3,405.2 | 3,200.0 | 2,871.0 | 2,001.6 | 1,227.9 | 990.6 | 748.7 |
| Net margin | 29.7% | 39.3% | 38.0% | 39.7% | 32.2% | 20.6% | 28.6% | 35.1% |
| |
| Diluted EPS | $4.29 | $7.10 | $6.69 | $6.02 | $16.95 | $10.58 | $3.38 | $6.64 |
| Shares outstanding (diluted) | 500.5 | 479.7 | 478.1 | 476.9 | 118.1 | 116.0 | 293.1 | 112.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|